Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review.

Peter GalleRichard S FinnCatherine Ruth MitchellKerigo NdiranguZahra RamjiGabrielle Sophie RedheadDavid James Pinato

Published in: Journal for immunotherapy of cancer (2024)

Checkpoint inhibitors for the treatment of cancer are immunogenic, with the incidence of treatment-emergent ADAs varying between individual therapies. It remains unclear what impact ADAs have on treatment outcomes.

Keyphrases

squamous cell carcinoma
risk factors
dna damage
cell proliferation
oxidative stress
drug induced
lymph node metastasis